Market Looks Tired
Biotech sector was the big winner yesterday, with the sector breaking out of ascending triangle on high volume.
AMGN's Vectibix drug was approved for colon cancer yesterday just before market closed. Stock closed @72.14. From Briefing.com "...We also note that back on Sep 14, Citigroup said they expected AMGN to react +5% to +10% with a full approval..." If the Citigroup analysts were right, then we can expect AMGN to hit abt $74 conservatively (1.05*71), which is right at about the 6 month high. Keep it in your radar for today.
0 Comments:
Post a Comment
<< Home